Search for European Projects

"The most significant advance in cancer therapeutics in recent years has been the introduction of monoclonal antibodies into widespread clinical usage. A consequence of this rapid emergence of antibodies as therapeutics is a lack of trained scientists within the EU with the requisite skills to enable antibody development at a globally competitive pace. The University of Birmingham (UoB) together w ...

In recent years the treatment paradigm for metastatic colorectal cancer (mCRC) has evolved in complexity to include newly developed targeted therapeutics. In 2004 bevacizumab (bvz) [Avastin] became the first anti-angiogenic drug to be licensed in malignant disease, based on the results of a randomised trial in advanced metastatic colorectal cancer. Nevertheless, over the past six year period emerg ...